Stay updated with the latest news, product updates, research insights, and important announcements from Generic Peptides.
After Ozempic, FDA's Next Peptide Fight Is Here: PSM Opposes All Seven Substances The deadline for comments guaranteed to reach the advisory committee has passed. BPC-157, TB-500, MOTS-c, Semax and three other peptides now face a decision that could close the…
FDA Staff Recommends Against All Seven Peptides Before July PCAC Vote: Why That May Be a Bad Idea Reading Time: 6 mins Regulatory News · FDA · PCAC · Peptide Compounding · 503A Bulks List By Generic Peptides Team FDA staff has now taken the clearest possible …
Epitalon After the July 2026 PCAC Review: Evidence and Regulatory Status By the Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public regulatory proceeding and is not medical or leg…
Semax After the July 2026 PCAC Review: Evidence and Regulatory Status By the Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article covers a public regulatory proceeding and is not medical or legal ad…
DSIP or Emideltide After the July 2026 PCAC Review: What the Evidence Shows By the Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public regulatory proceeding and is not medical or …
MOTS-c After the July 2026 PCAC Review: Human Evidence and Regulatory Status By the Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public regulatory proceeding and is not medical or…
What the evidence shows, what the PCAC recommendation means, and what still depends on FDA By the Generic Peptides Team · Updated September 4, 2026 Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public r…
What the research shows, what the advisory recommendation means, and what still depends on FDA By the Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article discusses scientific evidence and a public …
BPC-157 After the July 2026 PCAC Review: Evidence and Regulatory Status By the Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article discusses scientific evidence and a public FDA regulatory proceedi…
FDA Peptide Meeting July 2026: What PCAC Recommended for All Seven Peptides By the Generic Peptides Team Editorial disclosure: Generic Peptides sells peptides for laboratory research. This article explains a public regulatory proceeding and is not medical or …
The Peptide Boom Is Here: Why Buyers Are Looking Beyond GLP-1s in 2026 By Generic Peptides Team Peptides are no longer a niche topic hidden inside bodybuilding forums, longevity podcasts, or private biohacking groups. In 2026, they have moved into the center …
Pemvidutide's 48-Week Data: A Real MASH Contender — or Just Another Phase 2 Headline? What Altimmune Just Showed at EASL On May 28, 2026, at the European Association for the Study of the Liver (EASL) Congress in Barcelona, Altimmune unveiled the full 48-week …